Nosocomial and Community Acquired Legionella Pneumophila Pneumonia.
- Conditions
- Legionnaires' Disease
- Interventions
- Other: Data extraction from medical files
- Registration Number
- NCT04106037
- Lead Sponsor
- Dr Philippe CLEVENBERGH
- Brief Summary
Legionnaire's disease (LD) is a major cause of both community acquired and nosocomial pneumonia, with Legionella pneumophila serogroup A (Lp1) being the most virulent and the greatest cause of disease. Sample culture of low respiratory tract is considered the gold standard in the diagnosis of LD, however its sensitivity seems to be poor and its performance is technically demanding. The introduction of urinary antigen detection testing (LUA) brought a major advance in LD diagnosis, with upt to 95% of cases in Europe being diagnosed with this method. Despite the high sensitivity of LUA for Lp1, ranging from 80-90%, its negative predictive value is low in other serogroup than Lp1 and therefore, Legionella may be unrecognized as agent of pneumonia. Although underdiagnosed and underreported, LD represents the second most common cause of pneumonia requiring admission in intensive care unit (ICU). Average fatality rate of LD in Europe reaches 10%, but its mortality is considered to be even higher in nosocomial patients.
Despite the higher fatality rate in hospitalized LD patients, poor is the knowledge on the risk factors that could induce disease and that increase mortality in the hospitalized population affected by LD. In order to shed more light on this topic a cohort of patients diagnosed with LD in the last 3 years will be retrospectively examined.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years, from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre and the UZ Brussel Hospitals.
Pregnant women.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Legionnaires' disease Data extraction from medical files All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.
- Primary Outcome Measures
Name Time Method Severity respiratory failure 3 years Arterial pression of oxygen inferior to 600mmHg at diagnosis
All cause mortality 3 years All cause mortality
- Secondary Outcome Measures
Name Time Method Creatinine One day Creatinine level at diagnosis
Urea One day Urea level at diagnosis
Method of diagnosis One day Name of the method of diagnosis (urinary antigen, seroconversion, cultures).
Antibiotics One day Name of antibiotics given
Age One day Age at diagnosis
Sex One day Sex
Charlson comorbidity index One day This is a health tool that assesses the comorbidity risk associated to a series of conditions in order to offer medical specialists an informed decision making process in terms of specific screenings or medical procedures.The index accounts for the patient age and 16 different conditions, and ranges from 0 till 37.
Nosocomial disease (yes/no) One day Nosocomial cases of Legionnaires' disease are defined in this study as having an onset of symptoms more than 10 days after hospitalization.
Smoking status One day Smoking (yes/no) at diagnosis
Chest X Ray One day Descriptive analysis of Chest X Ray findings at diagnosis
C reactive protein One day C reactive protein level at diagnosis
White blood cells One day White blood cells level at diagnosis
Intensive care unit hospitalization One day Intensive care unit hospitalization (yes/no)
Antibiotic treatment duration up to 40 days Antibiotic treatment duration
Trial Locations
- Locations (3)
CHU St Pierre Hospital
🇧🇪Brussels, Belgium
Universitair Zienkenhuis Brussel
🇧🇪Brussels, Belgium
CHU Brugmann
🇧🇪Brussel, Belgium